Skip to main content
    T

    TherapeuticsMD Inc (TXMD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.81
    -0.06 (-3.21%)

    Market Cap: $21.64M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    TherapeuticsMD Inc (TXMD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    TherapeuticsMD reported revenue of $3.02M for the fiscal year ended Dec 31, 2025, up 71.6% from the year before. That year, net income was -$569.00K with a net margin of -18.8%, operating cash flow was $2.45M and free cash flow was $2.45M. The quarter ended Sep 30, 2026 had revenue of $1.26M and net income of $491.00K.

    Revenue and Margins

    The net margin was -18.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $19.36M, a compound annual decline of 18.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.02M+71.6%100.0%-145.3%-18.8%
    Dec 2024$1.76M+35.3%100.0%-347.1%-123.9%
    Dec 2023$1.30M-98.1%100.0%-654.6%-789.4%
    Dec 2022$69.96M+2619.1%98.0%1.7%160.1%
    Dec 2021$2.57M-96.0%45.5%-3092.8%-6700.9%
    Dec 2020$64.87M+30.7%75.4%-239.8%-282.9%
    Dec 2019$49.65M+208.4%87.2%-304.6%-354.8%
    Dec 2018$16.10M-4.0%83.0%-808.8%-823.7%
    Dec 2017$16.78M-13.3%84.3%-462.7%-458.5%
    Dec 2016$19.36MN/A78.4%-466.3%-464.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 223.0% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.02M$1.76M$1.30M$69.96M$2.57M$64.87M$49.65M$16.10M$16.78M$19.36M
    Cost of revenue$0$0$0$1.40M$1.40M$15.97M$6.33M$2.74M$2.64M$4.19M
    Gross profit$3.02M$1.76M$1.30M$68.57M$1.17M$48.90M$43.31M$13.36M$14.14M$15.17M
    Research and development$0$0$0$0$0$10.43M$19.79M$27.30M$33.85M$53.94M
    Operating income-$4.39M-$6.11M-$8.52M$1.19M-$79.58M-$155.54M-$151.21M-$130.22M-$77.63M-$90.25M
    Net income-$569.00K-$2.18M-$10.28M$112.00M-$172.41M-$183.52M-$176.15M-$132.62M-$76.93M-$89.88M
    EBITDA$398.00K-$1.20M-$6.82M$2.38M-$78.57M-$150.88M-$147.31M-$127.38M-$76.72M-$89.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.26M$869.00K$724.00K$893.00K$784.00K$952.00K$393.00K$667.00K$547.00K$234.00K$313.00K$502.00K
    Gross profit$1.26M$869.00K$724.00K$893.00K$784.00K$952.00K$393.00K$667.00K$547.00K$234.00K$313.00K$502.00K
    Operating income-$479.00K-$816.00K-$723.00K-$1.96M-$862.00K-$695.00K-$1.28M-$1.05M-$1.13M-$2.79M-$1.14M-$1.61M
    Net income$491.00K$155.00K$95.00K-$619.00K$152.00K$551.00K-$653.00K$252.00K-$609.00K-$1.09M-$734.00K-$883.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $975.00K by $6.51M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$37.66M$38.82M$43.31M$90.46M$169.47M$181.61M$265.99M$211.98M$143.23M$142.47M
    Current assets$14.45M$12.26M$11.80M$55.35M$119.47M$128.40M$208.42M$186.78M$139.55M$139.41M
    Cash and equivalents$7.48M$5.06M$4.33M$38.07M$64.91M$80.49M$160.83M$161.61M$127.14M$131.53M
    Total liabilities$10.78M$11.45M$14.02M$55.31M$263.09M$305.61M$256.78M$114.46M$13.32M$14.98M
    Short-term debt$975.00K$1.63M$1.47M$1.39M$188.27M$0$1.50MN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$237.70M$194.63M$73.38M$0$0
    Shareholder equity$26.88M$27.37M$29.29M$35.14M-$93.62M-$124.00M$9.20M$97.52M$129.91M$127.49M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$37.93M$37.53M$37.58M$37.66M$38.67M$38.50M$38.24M$38.82M$39.55M$40.13M$42.09M$43.31M
    Total liabilities$10.31M$10.40M$10.61M$10.78M$11.23M$11.21M$11.50M$11.45M$12.46M$12.46M$13.42M$14.02M
    Cash and equivalents$10.45M$9.19M$8.42M$7.48M$7.12M$6.07M$5.75M$5.06M$5.05M$5.23M$4.34M$4.33M
    Shareholder equity$27.62M$27.13M$26.97M$26.88M$27.44M$27.29M$26.74M$27.37M$27.09M$27.67M$28.66M$29.29M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$2.45M$1.17M-$23.08M$9.36M-$142.69M-$159.47M-$165.72M-$106.81M-$76.16M-$69.14M
    Capital expenditures$0$0$48.14M$355.00K$34.00K$207.00K$2.45M$217.04K$61.82K$396.15K
    Free cash flow$2.45M$1.17M-$71.22M$9.00M-$142.73M-$159.68M-$168.17M-$107.03M-$76.22M-$69.54M
    Investing cash flow$0$0$0-$355.00K-$2.22M-$1.60M-$23.89M-$21.50M-$827.11K-$1.26M
    Financing cash flow$0$0$3.15M-$235.21M$129.55M$80.72M$188.83M$162.79M$72.58M$137.23M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$1.27M$787.00K$936.00K$375.00K$999.00K$394.00K$686.00K$17.00K-$71.00K$1.45M-$229.00K-$4.96M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$7.84M$0
    Free cash flowN/AN/A$936.00K$375.00K$999.00K$394.00K$686.00K$17.00K-$71.00K$1.45M-$8.07M-$4.96M
    Last 12 quarters

    Frequently Asked Questions About TXMD

    What is TherapeuticsMD's annual revenue?

    TherapeuticsMD reported revenue of $3.02M for the fiscal year ended Dec 31, 2025.

    How fast is TherapeuticsMD's revenue growing?

    Revenue was up 71.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -64.9%.

    Is TherapeuticsMD profitable?

    No. TherapeuticsMD reported net income of -$569.00K for the fiscal year ended Dec 31, 2025, with a net margin of -18.8%.

    How much free cash flow does TXMD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $2.45M minus capital expenditures of $0 produced free cash flow of $2.45M.

    How much debt does TherapeuticsMD have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $975.00K and cash and equivalents of $7.48M.